RecruitingPhase 2NCT03910738

TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis


Sponsor

University Hospital, Strasbourg, France

Enrollment

40 participants

Start Date

Oct 29, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

Centra nervous system (CNF) damage in multiple sclerosis (MS), are mainly attributed to myelin destruction, axonal abnormalities and subsequent degeneration, and are responsible for serious deficiencies. Current therapies are focused on the treatment of inflammation with several types of anti-inflammatory agents. However, there is an urgent need for innovative therapies promoting neuroregeneration and particularly myelin repair. It has been demonstrated that testosterone can act through neural androgen receptors to promote proliferation and differentiation of oligodendrocyte precursors into mature oligodendrocytes in a cuprizone-induced animal model of demyelination. The rare clinical trials on testosterone are mainly exploratory. Here, we sought to demonstrate an effect of testosterone supplementation in testosterone-deficient patients in a multicenter, randomized, parallel-group, double-blind, placebo-controlled phase 2 trial. The main objective will be to determine the neuroprotective and remyelinating effects of testosterone using tensor diffusion imaging techniques and thalamic atrophy analyzes. As secondary objectives, we would like to study the impact of testosterone supplementation on other conventional and unconventional MRI parameters and on clinical outcomes (cognition, fatigue, quality of life, impact on work / activity and anxiety / depression).


Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing whether testosterone therapy can protect the brain and help repair myelin — the protective coating around nerve fibers — in men with relapsing-remitting multiple sclerosis who are already on stable disease-modifying treatment. **You may be eligible if...** - You are a man between 18 and 55 years old - You have a confirmed diagnosis of relapsing-remitting MS (RRMS) - You have been on one of these MS medications for at least one year: natalizumab, fingolimod, ponesimod, ocrelizumab, or ofatumumab - You are enrolled in the French social health insurance system **You may NOT be eligible if...** - You are not currently on one of the qualifying MS medications - You have conditions that make testosterone therapy unsafe (e.g., prostate issues, cardiovascular problems) - You have recently changed your MS medication Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection

Active treatment (Nebido® Testosterone Undecanoate ) will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)

DRUGPlacebo 4 mL Solution for Injection

Placebo will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)

PROCEDUREMRI

Conventional MS sequences (OFSEP recommendations) and unconventional MRI sequences (Baseline, week 30 and 66)

BEHAVIORALAssessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities

BICAMS; SF-36 and EQ-5D-3L; MFIS; HADS; WPAI:MS (at baseline, week 30 and 66)

BEHAVIORALAssessment of disability

EDSS (Baseline, week 30 and 66)


Locations(5)

CHU de Besançon

Besançon, France

CHU Nancy

Nancy, France

Hôpital Pitié-Salpêtrière

Paris, France

CHU de Rennes/Pontchaillou

Rennes, France

CHRU de Strasbourg

Strasbourg, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03910738


Related Trials